“It takes sex to a whole new level.”

That’s how a 52-year-old Nashville woman describes the effect of taking the so-called female Viagra pill.

Amanda Blackie Parrish was engaged in the clinical trials for the drug fibanserin — soon to be marketed under the brand name Addyi — when after just two weeks she started to feel a “flutter … down there,” she told The Post on Thursday.

Parrish said after four years of marriage, she’d lost all sexual desire.

This is the biggest breakthrough in women’s sexual health since the advent of the pill. - Sally Greenberg, executive director of the National Consumers League

Parrish was so excited about the turn of events, she said, that she texted her husband, Ben, a lawyer, during the middle of a work day.

“Would you like to have ME for lunch?” she asked.

That was five long years ago.

Since the trials ended, sex has gone back to being a “constant battle and struggle,” she moaned.

That’s why she and Ben can’t wait for Oct. 17 — the day the little pink female libido pill will hit pharmacy shelves.

“It’s the answer to my prayers,” Parrish told The Post.

Pharma giant Valeant hopes it is the answer to its prayers, as well. It announced Thursday that it was paying $1 billion for Sprout Pharmaceuticals, the closely held company behind the pink pill.

The deal was signed one day after the Food and Drug Administration approved Addyi on Tuesday.

The drug’s approval had been long sought by a coalition of women and consumer groups, whose campaign, “Even the Score,” argued that there were already 26 FDA-approved drugs for male sexual dysfunction — but none for women.

“This is the biggest breakthrough in women’s sexual health since the advent of the pill,” said Sally Greenberg, executive director of the National Consumers League, one of 26 groups that pressed the FDA to approve Addyi.

Studies quoted by the group indicate that 10 percent of US women suffer from the lack of desire that the drug will treat.

“There will be millions of women who are going to go their doctors and say, ‘I want this treatment,’” Greenberg said.

Addyi works on brain chemistry, increasing dopamine and norepinephrine levels, and its side effects include nausea and dizziness.

Greenberg and Parrish both downplayed the negatives.

“Male drugs were fast-tracked and they can kill you,” said Greenberg. The male drug side effects include blindness, heart attacks and strokes.

Whatever the side effects, sex sells.

Viagra has added close to $2 billion a year in revenues to Pfizer since 2003 — a fact that has given drug companies the hots for Addyi.

The purchase by Valeant is a coup for its CEO, J. Michael Pearson — who has built the company into a powerhouse with a slew of acquisitions, starting in eye care and branching out into gastrointestinal drugs.

But a blockbuster drug has long eluded Pearson, whose company has a medicine cabinet full of more pedestrian offerings. The CEO called the deal “the perfect opportunity to establish a new portfolio of important medications that uniquely impact women.”

Parrish, however, had her own warning for Addyi.

While the pill took sex to a new intimate level for her and her husband, she cautioned, “I don’t want people to think it makes you so horny you want to jump everyone’s bones.”